Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Oligonucleotides, Equipment/Synthesizer), By Application (PCR Primers, PCR Assays & Panels), By Region, And Segment Forecasts, 2024 - 2030
Oligonucleotide Synthesis Market Growth & Trends
The global oligonucleotide synthesis market size is projected to reach USD 8.53 billion by 2030, registering a CAGR of 13.21% from 2024 to 2030, according to a new report by Grand View Research, Inc. The strong pipeline of oligonucleotide therapeutics in clinical trials, advancements in gene editing technologies, and increasing R&D spending by biotechnology companies are some of the major factors driving the market growth.
Oligonucleotide therapeutics participants are present in the late stages of clinical trials and are expected to be approved & commercialized over the forecast period. Companies have increased investments to develop oligonucleotide-based therapeutics. In October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.
Government bodies, such as the Centers for Medicaid & Medicare Services for labs, the Federal Trade Commission for marketing, and the FDA for kits & information, have played a key role in the success of genomics, as they have been involved in monitoring the safe, appropriate, and accurate application of genomics & genetic tests. International funding bodies, such as NIH and Wellcome Trust, are engaged in providing funds for genetic studies, which is expected to fuel genomic studies in developed and emerging economies.
In May 2021, the UK government announced a funding of USD 43.4 million (GBP 37 million) for genomics research and data-driven initiatives, delivered via the UK Functional Genomics Initiative and Genome UK Implementation Plan, which was started in September 2019. The Genome UK strategy will be implemented with the help of the Genomics England project, which will receive USD 19.9 million (GBP 17 million) to investigate the potential value of newborn sequencing.
Oligonucleotide Synthesis Market Report Highlights
- Based on product & services, the service segment dominated the market with more than 37.0% share in 2023 owing to the growing demand for specialized services and increasing number of demands for outsourcing services
- Based on application, the PCR primers segment held the largest market share in 2023. Their crucial role in amplifying specific DNA or RNA sequences makes them an essential component of the market
- North America dominated the market owing to factors such as increasing the presence of key players, increasing demand for synthetic DNA & RNA sequences in various applications, and favorable regulatory scenario
- In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product & service
- 1.2.2. Application
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Landscape Insights
- Chapter 3. Oligonucleotide Synthesis Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
- 3.2.1.2. Changing regulatory environments for genetic research and its applications in healthcare
- 3.2.1.3. High R&D spending of pharmaceutical & biotechnology companies
- 3.2.1.4. Increased public-private spending on genomics
- 3.2.1.5. Technological advancements in gene editing technologies
- 3.2.2. Market restraint analysis
- 3.2.2.1. Need for advanced oligo synthesis solutions
- 3.2.2.2. High cost associated with genomics research
- 3.2.2.3. Lack of skilled professionals and research support in undeveloped countries
- 3.3. Business Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
- Chapter 4. Oligonucleotide Synthesis Market: Product & Service Estimates & Trend Analysis
- 4.1. Product & Service Market Share, 2023 & 2030
- 4.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 4.2.1. Oligonucleotides
- 4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.1.2. DNA
- 4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.1.2.2. Column-based
- 4.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.1.2.3. Array-based
- 4.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.1.3. RNA
- 4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.1.3.2. By Technology
- 4.2.1.3.2.1. Column-based
- 4.2.1.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.1.3.2.2. Array-based
- 4.2.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.1.3.3. By Type
- 4.2.1.3.3.1. Short RNA Oligos (<65 nt)
- 4.2.1.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.1.3.3.2. Long RNA Oligos (>65 nt)
- 4.2.1.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.1.3.3.3. CRISPR (sgRNA)
- 4.2.1.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.2. Equipment/Synthesizer
- 4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.3. Reagents
- 4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4. Services
- 4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.2. DNA
- 4.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.2.2. Custom oligo synthesis services
- 4.2.4.2.2.1. 25 nmol
- 4.2.4.2.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.2.2.2. 50 nmol
- 4.2.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.2.2.3. 200 nmol
- 4.2.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.2.2.4. 1000 nmol
- 4.2.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.2.2.5. 10000 nmol
- 4.2.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.2.3. Modification services
- 4.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.2.4. Purification services
- 4.2.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.3. RNA
- 4.2.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.3.2. Custom oligo synthesis services
- 4.2.4.3.2.1. 25 nmol
- 4.2.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.3.2.2. 100 nmol
- 4.2.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.3.2.3. 1000 nmol
- 4.2.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.3.2.4. 10000 nmol
- 4.2.4.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.3.3. Modification services
- 4.2.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.2.4.3.4. Purification services
- 4.2.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 5. Oligonucleotide Synthesis Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2023 & 2030
- 5.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 5.2.1. PCR primers
- 5.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.1.2. Academic research institutes
- 5.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.1.2.2. Diagnostic laboratories
- 5.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.1.2.3. Pharmaceutical - biotechnology companies
- 5.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.2. PCR assays and panels
- 5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.2.2. Academic research institutes
- 5.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.2.2.2. Diagnostic laboratories
- 5.2.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.2.2.3. Pharmaceutical - biotechnology companies
- 5.2.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.3. Sequencing
- 5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.3.2. Academic research institutes
- 5.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.3.2.2. Diagnostic laboratories
- 5.2.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.3.2.3. Pharmaceutical - biotechnology companies
- 5.2.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.4. DNA microarrays
- 5.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.4.2. Academic research institutes
- 5.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.4.2.2. Diagnostic laboratories
- 5.2.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.4.2.3. Pharmaceutical - biotechnology companies
- 5.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.5. Fluorescence in situ hybridization (FISH)
- 5.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.5.2. Academic research institutes
- 5.2.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.5.2.2. Diagnostic laboratories
- 5.2.5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.5.2.3. Pharmaceutical - biotechnology companies
- 5.2.5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.6. Antisense oligonucleotides
- 5.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.6.2. Academic research institutes
- 5.2.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.6.2.2. Diagnostic laboratories
- 5.2.6.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.6.2.3. Pharmaceutical - biotechnology companies
- 5.2.6.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.2.7. Other applications
- 5.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 6. Oligonucleotide Synthesis Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Share Analysis, 2023 & 2030
- 6.2. North America
- 6.2.1. U.S.
- 6.2.1.1. Key country dynamics
- 6.2.1.2. Regulatory framework
- 6.2.1.3. Competitive scenario
- 6.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 6.2.2. Canada
- 6.2.2.1. Key country dynamics
- 6.2.2.2. Regulatory framework
- 6.2.2.3. Competitive scenario
- 6.2.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3. Europe
- 6.3.1. UK
- 6.3.1.1. Key country dynamics
- 6.3.1.2. Regulatory framework
- 6.3.1.3. Competitive scenario
- 6.3.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.2. Germany
- 6.3.2.1. Key country dynamics
- 6.3.2.2. Regulatory framework
- 6.3.2.3. Competitive scenario
- 6.3.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.3. France
- 6.3.3.1. Key country dynamics
- 6.3.3.2. Regulatory framework
- 6.3.3.3. Competitive scenario
- 6.3.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.4. Italy
- 6.3.4.1. Key country dynamics
- 6.3.4.2. Regulatory framework
- 6.3.4.3. Competitive scenario
- 6.3.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.5. Spain
- 6.3.5.1. Key country dynamics
- 6.3.5.2. Regulatory framework
- 6.3.5.3. Competitive scenario
- 6.3.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.6. Norway
- 6.3.6.1. Key country dynamics
- 6.3.6.2. Regulatory framework
- 6.3.6.3. Competitive scenario
- 6.3.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.7. Sweden
- 6.3.7.1. Key country dynamics
- 6.3.7.2. Regulatory framework
- 6.3.7.3. Competitive scenario
- 6.3.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.8. Denmark
- 6.3.8.1. Key country dynamics
- 6.3.8.2. Regulatory framework
- 6.3.8.3. Competitive scenario
- 6.3.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4. Asia Pacific
- 6.4.1. Japan
- 6.4.1.1. Key country dynamics
- 6.4.1.2. Regulatory framework
- 6.4.1.3. Competitive scenario
- 6.4.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. China
- 6.4.2.1. Key country dynamics
- 6.4.2.2. Regulatory framework
- 6.4.2.3. Competitive scenario
- 6.4.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. India
- 6.4.3.1. Key country dynamics
- 6.4.3.2. Regulatory framework
- 6.4.3.3. Competitive scenario
- 6.4.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.4. Australia
- 6.4.4.1. Key country dynamics
- 6.4.4.2. Regulatory framework
- 6.4.4.3. Competitive scenario
- 6.4.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.5. South Korea
- 6.4.5.1. Key country dynamics
- 6.4.5.2. Regulatory framework
- 6.4.5.3. Competitive scenario
- 6.4.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.6. Thailand
- 6.4.6.1. Key country dynamics
- 6.4.6.2. Regulatory framework
- 6.4.6.3. Competitive scenario
- 6.4.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Latin America
- 6.5.1. Brazil
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework
- 6.5.1.3. Competitive scenario
- 6.5.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. Mexico
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework
- 6.5.2.3. Competitive scenario
- 6.5.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. Argentina
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework
- 6.5.3.3. Competitive scenario
- 6.5.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. MEA
- 6.6.1. South Africa
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework
- 6.6.1.3. Competitive scenario
- 6.6.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.2. Saudi Arabia
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.3. UAE
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Regulatory framework
- 6.6.3.3. Competitive scenario
- 6.6.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.4. Kuwait
- 6.6.4.1. Key country dynamics
- 6.6.4.2. Regulatory framework
- 6.6.4.3. Competitive scenario
- 6.6.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Company/Competition Categorization
- 7.2. Strategy Mapping
- 7.3. Company Market Position Analysis, 2023
- 7.4. Company Profiles/Listing
- 7.4.1. Thermo Fisher Scientific, Inc.
- 7.4.1.1. Company overview
- 7.4.1.2. Financial performance
- 7.4.1.3. Product benchmarking
- 7.4.1.4. Strategic initiatives
- 7.4.2. Merck KGaA
- 7.4.2.1. Company overview
- 7.4.2.2. Financial performance
- 7.4.2.3. Product benchmarking
- 7.4.2.4. Strategic initiatives
- 7.4.3. Danaher Corporation
- 7.4.3.1. Company overview
- 7.4.3.2. Financial performance
- 7.4.3.3. Product benchmarking
- 7.4.3.4. Strategic initiatives
- 7.4.4. Dharmacon Inc.
- 7.4.4.1. Company overview
- 7.4.4.2. Financial performance
- 7.4.4.3. Product benchmarking
- 7.4.4.4. Strategic initiatives
- 7.4.5. Agilent Technologies
- 7.4.5.1. Company overview
- 7.4.5.2. Financial performance
- 7.4.5.3. Product benchmarking
- 7.4.5.4. Strategic initiatives
- 7.4.6. Bio-synthesis
- 7.4.6.1. Company overview
- 7.4.6.2. Financial performance
- 7.4.6.3. Product benchmarking
- 7.4.6.4. Strategic initiatives
- 7.4.7. Kaneka Eurogentec S.A
- 7.4.7.1. Company overview
- 7.4.7.2. Financial performance
- 7.4.7.3. Product benchmarking
- 7.4.7.4. Strategic initiatives
- 7.4.8. LGC Biosearch Technologies
- 7.4.8.1. Company overview
- 7.4.8.2. Financial performance
- 7.4.8.3. Product benchmarking
- 7.4.8.4. Strategic initiatives
- 7.4.9. Biolegio
- 7.4.9.1. Company overview
- 7.4.9.2. Financial performance
- 7.4.9.3. Product benchmarking
- 7.4.9.4. Strategic initiatives
- 7.4.10. Twist Bioscience
- 7.4.10.1. Company overview
- 7.4.10.2. Financial performance
- 7.4.10.3. Product benchmarking
- 7.4.10.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook